These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 26337073)

  • 21. Characteristics of recurrence in area postrema-onset NMO spectrum disorder - a retrospective cohort study.
    Zhang X; Wu J; Lin J; Lin S; Lin A
    BMC Neurol; 2024 May; 24(1):165. PubMed ID: 38773402
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan.
    Kitley J; Leite MI; Nakashima I; Waters P; McNeillis B; Brown R; Takai Y; Takahashi T; Misu T; Elsone L; Woodhall M; George J; Boggild M; Vincent A; Jacob A; Fujihara K; Palace J
    Brain; 2012 Jun; 135(Pt 6):1834-49. PubMed ID: 22577216
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The relationship between aquaporin-4 antibody status and visual tract integrity in neuromyelitis optica spectrum disorders: A visual evoked potential study.
    Barć K; Gospodarczyk-Szot K; Nojszewska M; Podlecka-Piętowska A; Zakrzewska-Pniewska B
    Mult Scler Relat Disord; 2020 Sep; 44():102265. PubMed ID: 32575026
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neuromyelitis optica spectrum disorders with a benign course. Analysis of 544 patients.
    Lana-Peixoto MA; Talim NC; Callegaro D; Marques VD; Damasceno A; Becker J; Gonçalves MVM; Sato H;
    Mult Scler Relat Disord; 2023 Jul; 75():104730. PubMed ID: 37156036
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Aquaporin 4 IgG serostatus and outcome in recurrent longitudinally extensive transverse myelitis.
    Jiao Y; Fryer JP; Lennon VA; McKeon A; Jenkins SM; Smith CY; Quek AM; Weinshenker BG; Wingerchuk DM; Shuster EA; Lucchinetti CF; Pittock SJ
    JAMA Neurol; 2014 Jan; 71(1):48-54. PubMed ID: 24248262
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical characteristics of late-onset neuromyelitis optica spectrum disorder.
    Min W; Zhang L; Wang S; Xue M; Guo C; Zhu M
    Mult Scler Relat Disord; 2023 Feb; 70():104517. PubMed ID: 36708681
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Early predictors of disability of paediatric-onset AQP4-IgG-seropositive neuromyelitis optica spectrum disorders.
    Camera V; Messina S; Elhadd KT; Sanpera-Iglesias J; Mariano R; Hacohen Y; Dobson R; Meletti S; Wassmer E; Lim MJ; Huda S; Hemingway C; Leite MI; Ramdas S; Palace J
    J Neurol Neurosurg Psychiatry; 2022 Jan; 93(1):101-111. PubMed ID: 34583946
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Clinical characteristics and follow-up of pediatric patients with neuromyelitis optica and neuromyelitis optica spectrum disorders].
    Yun W; Weihua Z; Xiaotun R; Jiuwei L; Xinying Y; Junlan L; Changhong D; Chunhong C; Haitao R; Liying C; Fang F
    Zhonghua Er Ke Za Zhi; 2015 Apr; 53(4):268-73. PubMed ID: 26182501
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical and paraclinical profile of neuromyelitis optic spectrum disorder in a peruvian cohort.
    Castro-Suarez S; Guevara-Silva E; Osorio-Marcatinco V; Alvarez-Toledo K; Meza-Vega M; Caparó-Zamalloa C
    Mult Scler Relat Disord; 2022 Aug; 64():103919. PubMed ID: 35691236
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predictive value of MRI parameters in severity and recovery of first-episode myelitis in aquaporin-4 antibody disease.
    Murchison A; Kitley J; Leite MI; Küker W; Palace J
    J Neurol Sci; 2015 Aug; 355(1-2):49-53. PubMed ID: 26026944
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Longitudinally extensive transverse myelitis immune-mediated in aquaporin-4 antibody negative patients: Disease heterogeneity.
    Carnero Contentti E; Hryb JP; Morales S; Gomez A; Chiganer E; Di Pace JL; Lessa C; Perassolo M
    J Neurol Sci; 2017 Feb; 373():134-137. PubMed ID: 28131170
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Late onset neuromyelitis optica spectrum disorders (LONMOSD) from a nationwide Portuguese study: Anti-AQP4 positive, anti-MOG positive and seronegative subgroups.
    Santos E; Moura J; Samões R; Sousa AP; Mendonça T; Abreu P; Guimarães J; Correia I; Durães J; Sousa L; Ferreira J; de Sá J; Sousa F; Sequeira M; Correia AS; André AL; Basílio C; Arenga M; Marques IB; Perdigão S; Alves I; Santos M; Salgado V; Palos A; Guerreiro R; Isidoro L; Boleixa D; Carneiro P; Neves E; Silva AM; Gonçalves G; Sá MJ
    Mult Scler Relat Disord; 2022 Jul; 63():103845. PubMed ID: 35594635
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Distinctive characteristics of early-onset and late-onset neuromyelitis optica spectrum disorders.
    Zhang LJ; Yang LN; Li T; Wang J; Qi Y; Zhang DQ; Yang CS; Yang L
    Int J Neurosci; 2017 Apr; 127(4):334-338. PubMed ID: 27788616
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical features of neuromyelitis optica in a large Japanese cohort: comparison between phenotypes.
    Nagaishi A; Takagi M; Umemura A; Tanaka M; Kitagawa Y; Matsui M; Nishizawa M; Sakimura K; Tanaka K
    J Neurol Neurosurg Psychiatry; 2011 Dec; 82(12):1360-4. PubMed ID: 21665917
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease.
    Höftberger R; Sepulveda M; Armangue T; Blanco Y; Rostásy K; Calvo AC; Olascoaga J; Ramió-Torrentà L; Reindl M; Benito-León J; Casanova B; Arrambide G; Sabater L; Graus F; Dalmau J; Saiz A
    Mult Scler; 2015 Jun; 21(7):866-874. PubMed ID: 25344373
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neuromyelitis Optica spectrum disorders in Argentina: A hospital-based study.
    Villa AM; Manin A; Seimandi C; Finkelsteyn AM; Ramos G; Tenembaum S
    Mult Scler Relat Disord; 2023 Nov; 79():105018. PubMed ID: 37806234
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The clinical characteristics of AQP4 antibody positive NMO/SD in a large cohort of Chinese Han patients.
    ZhangBao J; Zhou L; Li X; Cai T; Lu J; Lu C; Zhao C; Quan C
    J Neuroimmunol; 2017 Jan; 302():49-55. PubMed ID: 27988051
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical features and sera anti-aquaporin 4 antibody positivity in patients with demyelinating disorders of the central nervous system from Tianjin, China.
    Yang CS; Zhang DQ; Wang JH; Jin WN; Li MS; Liu J; Zhang CJ; Li T; Shi FD; Yang L
    CNS Neurosci Ther; 2014 Jan; 20(1):32-9. PubMed ID: 23890015
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical and radiological profile of neuromyelitis optica spectrum disorders in an Ecuadorian cohort.
    Edgar Patricio CD; Eleanor THG; Francisco José CZ; Gabriela ACM; Hyland AO; Fernando GL; María TA; Beatriz N; Marcos SD; Alfredo GPW
    Mult Scler Relat Disord; 2020 Sep; 44():102208. PubMed ID: 32562910
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorder Patients in Turkish Cohort: Demographic, Clinical, and Laboratory Features.
    Altintas A; Karabudak R; Balci BP; Terzi M; Soysal A; Saip S; Tuncer Kurne A; Uygunoglu U; Nalbantoglu M; Gozubatik Celik G; Isik N; Celik Y; Gokcay F; Duman T; Boz C; Yucesan C; Mangan MS; Celebisoy N; Diker S; Colpak Isikay I; Kansu T; Siva A
    Neurologist; 2015 Oct; 20(4):61-6. PubMed ID: 26468870
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.